Newsol Technologies Inc. is dedicated to the development and commercialization of intelligent healthcare devices geared to the delivery of medical care at clinics, at hospitals and especially for home.
Newsol's mission is to become the world’s premiere developer of innovative dialysis systems that optimize, in real time, the management and treatment of End Stage Renal Disease (ESRD) (also known as End Stage Renal Failure or ESRF) resulting in improved patient health outcomes and running cost. ESRD is a chronic illness with no cure; however it can be managed with effective long-term treatment in the form of dialysis.
There are two major forms of kidney dialysis; Hemodialysis (HD) and Peritoneal Dialysis (PD). Newsol specializes in PD.
Newsol Technologies Inc. was founded in 1997. Mr. Joseph E. Dadson (View Bio), a co-founder, is a professional engineer who has been at the forefront of innovations in dialysis technology. Mr. Dadson’s extensive technological and entrepreneurial experience in the development of peritoneal dialysis instrumentation for the management of ESRF led to his developing the Automated Peritoneal Dialysis (APD) machine and other essential PD products, which have revolutionized dialysis therapy for patients with kidney failure.
Newsol’s product line, the SmartPD™ System, is yet another major step forward for Mr. Dadson, and presents a major advance in this field. It is an outcome of over 25 years of dialogue and collaboration with seasoned nephrologist specialists, passionate about peritoneal dialysis, with extensive peritoneal dialysis treatment experience. The SmartPD™ System is a fully developed portable & computerized integrated APD machine, complete with associated disposable accessories for the treatment of ESRD.
This innovative machine provides full data management capability to revolutionize PD therapy for patients with kidney failure. It is significant enough to influence and control the future direction of new peritoneal dialysis products, the treatment and the economics, and may assist in making PD the first choice of dialysis treatment in the targeted markets and in the emerging countries where PD growth is substantially above average. The technology and its applications are both protected by extensive global patents.